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Presynaptic accumulation of a-synuclein
causes synaptopathy and progressive
neurodegeneration in Drosophila
Jessika C. Bridi,1* Erika Bereczki,2 Saffron K. Smith,3 Gonçalo M. Poças,4,5
Benjamin Kottler,1 Pedro M. Domingos,4 Christopher J. Elliott,3 Dag Aarsland6,7 and
Frank Hirth1
* Present address: Laboratory of Molecular and Functional Neurobiology, Department of Pharmacology, Institute of Biomedical
Sciences, University of S~ao Paulo, S~ao Paulo 05508-000, Brazil.
Alpha-synuclein (a-syn) mislocalization and accumulation in intracellular inclusions is the major pathological hallmark of degen-
erative synucleinopathies, including Parkinson’s disease, Parkinson’s disease with dementia and dementia with Lewy bodies.
Typical symptoms are behavioural abnormalities including motor deficits that mark disease progression, while non-motor symp-
toms and synaptic deficits are already apparent during the early stages of disease. Synucleinopathies have therefore been considered
synaptopathies that exhibit synaptic dysfunction prior to neurodegeneration. However, the mechanisms and events underlying syn-
aptopathy are largely unknown. Here we investigated the cascade of pathological events underlying a-syn accumulation and tox-
icity in a Drosophila model of synucleinopathy by employing a combination of histological, biochemical, behavioural and electro-
physiological assays. Our findings demonstrate that targeted expression of human a-syn leads to its accumulation in presynaptic
terminals that caused downregulation of synaptic proteins, cysteine string protein, synapsin, and syntaxin 1A, and a reduction in
the number of Bruchpilot puncta, the core component of the presynaptic active zone essential for its structural integrity and func-
tion. These a-syn-mediated presynaptic alterations resulted in impaired neuronal function, which triggered behavioural deficits in
ageing Drosophila that occurred prior to progressive degeneration of dopaminergic neurons. Comparable alterations in presynaptic
active zone protein were found in patient brain samples of dementia with Lewy bodies. Together, these findings demonstrate that
presynaptic accumulation of a-syn impairs the active zone and neuronal function, which together cause synaptopathy that results
in behavioural deficits and the progressive loss of dopaminergic neurons. This sequence of events resembles the cytological and be-
havioural phenotypes that characterise the onset and progression of synucleinopathies, suggesting that a-syn-mediated synaptop-
athy is an initiating cause of age-related neurodegeneration.
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Introduction
Synucleinopathies are characterized by intraneuronal
inclusions called Lewy bodies (LB) that are mainly
formed of misfolded and aggregated forms of the pre-
synaptic protein a-synuclein (a-syn).1–4 These include
dementia with LB (DLB) as well as Parkinson’s disease
with dementia (PDD) and Parkinson’s disease.
Parkinson’s disease is mainly characterized by the pro-
gressive loss of dopaminergic (DA) neurons in the sub-
stantia nigra pars compacta (SN), thereby depleting
dopamine levels in synaptic terminals of the dorsal
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striatum.5–7 The resulting regulatory imbalance in the
basal ganglia causes a range of behavioural symptoms
including bradykinesia, uncontrollable tremor at rest, pos-
tural impairment and rigidity.8–10
Although the majority of Parkinson’s disease cases are
sporadic, several genes including LRRK2, Parkin, PINK1,
DJ-1, GBA and SNCA contribute to heritable cases of
the disease.11,12 However, among Parkinson’s disease-
related genes identified, the SNCA gene encoding a-syn
remains the most potent culprit underlying Parkinson’s
disease, with a key pathogenic role both in familial and
sporadic cases.13,14 Several point mutations in SNCA and
increased gene dosage caused by duplication or triplica-
tion of the gene locus, are causally related to severe
forms of Parkinson’s disease.15,16 These findings suggest
a causal relationship between a-syn levels and the severity
of cognitive decline, motor and non-motor symptoms,
and neurodegeneration.5,17
Although the mechanisms underlying a-syn toxicity
remain unclear, proteinaceous inclusions enriched with
a-syn were found not only in LB within the neuronal
soma but also in axonal processes.18 Most importantly,
a-syn micro-aggregates were found to be enriched in the
presynaptic terminals of DLB patients19 along with phos-
phorylated a-syn, which is believed to disrupt synaptic
structure and function.20 These findings suggest that
a-syn accumulation may cause a toxic gain of function
phenotype at the synapse, which impairs its function and
connectivity, ultimately causing synaptopathy.
In line with this hypothesis, classical motor symptoms
in Parkinson’s disease become clinically apparent only
when 60% of DA striatal terminals were already lost,
while the loss of DA neurons in the SN is only 30%.21
Corroborating these observation, it is well acknowledged
that the onset of Parkinson’s disease initiates at least
20 years prior to the detection of classical motor pheno-
types, a period known as the prodromal phase.16,22,23 It
has been suggested that during this phase, a large number
of proteins involved in synaptic transmission are affected,
as indicated by their altered expression levels in
Parkinson’s disease and DLB patients.24,25 These findings
are in agreement with positron emission tomography of
early-stage Parkinson’s disease patients who presented ex-
tensive axonal damage and diminished nigrostriatal path-
way connectivity.26 Therefore, it has been hypothesized
that neurodegeneration in Parkinson’s disease and DLB
follows a dying back-like pathomechanism, where degen-
eration of synapses and axonal connections precedes the
loss of neurons, classifying them as synaptopathies.5,27
However, it remains unclear how a-syn accumulation
impairs synaptic homeostasis, its structure and function,
ultimately leading to neurodegeneration.
Here we investigated the succession of events caused by
cell and tissue-specific accumulation of a-syn. We
employed a Drosophila model of synucleinopathy that
expresses human wild-type a-syn, and analysed post-
mortem tissue of Parkinson’s disease and DLB patients.
Our findings demonstrate that a-syn accumulates in, and
alters the presynaptic terminal, especially the active zone
(AZ), which was also observed in the prefrontal cortex
of DLB patients. In Drosophila, these alterations caused
neuronal dysfunction and behavioural deficits that pre-
ceded degenerative loss of DA neurons—cytological and
behavioural phenotypes that resemble the onset and pro-
gression of synucleinopathies. Together these findings
provide experimental evidence that presynaptic accumula-
tion of a-syn causes synaptopathy and progressive
neurodegeneration.
Materials and methods
Fly stocks and husbandry
All fly stocks were maintained in standard cornmeal
media at 25C in a 12 h light/dark cycle, unless for age-
ing experiments where flies were kept in 15% yeast/sugar
media.28–30 Strains used were Oregon R, W1118, nSyb-
gal4 (a kind gift from Dr Sean Sweeney), TH-gal4,31
UAS-EGFP, UAS-WT-a-syn-EGFP.32
Immunofluorescence
Drosophila larval neuromuscular junction (NMJ) dissec-
tions were carried out according to established protocol33
and fixed either with 3.5% formaldehyde for 25min or
Bouin’s fixative (Sigma) for 5min. Primary antibodies used
were anti-HRP (1:200—Immunochemicals 123–605-021),
anti-CSP (1:200—DSHB), anti-Synapsin (1:50—DSHB),
anti-nSynaptobrevin (1:15034; a kind gift from Dr Hugo
Bellen, Baylor College of Medicine), anti-Synaptotagmin
(1:100091; a kind gift from Dr Sean Sweeney, University
of York), anti-SNAP-25 (1:10035; a kind gift from
Dr David Deitcher, Cornell University), anti-GFP
(1:500—Thermo Fischer A6455), anti-BRP (1:50—DSHB).
Adult CNS preparations were carried out as described pre-
viously.30 The primary antibodies used were anti-TH
(1:50—ImmunoStar) and anti-GFP (1:500—Thermo Fischer
Scientific A6455). Secondary antibodies were Alexa fluor
488 and 568 (1:150; Invitrogen); for details see
Supplementary material.
Imaging and analysis
Z-stacks of NMJ synapses innervating muscle 6/7 of
Segment 3 were captured with a Nikon A1R confocal or
Leica TCS SP5 microscopes. The adult Drosophila brain
images were acquired using Nikon A1R confocal for DA
neuron cluster analysis. The instant super resolution
structured illumination microscopy (iSIM) was performed
using Nikon Eclipse Ti-E Inverted microscope to image
both for adult CNS and NMJ preparations.
For the fluorescence quantification, to build up the
ratio between GFP signal in the synaptic boutons and
axons, the intensity of 10 synaptic boutons (labelled with







































































anti-CSP) and 10 axonal regions (positive for anti-HRP
and negative for anti-CSP) were quantified per NMJ.
Thus, each n number represents the average value
obtained from the division of fluoresce intensity of synap-
tic boutons/axon in each NMJ. For fluorescence quantifi-
cations of Synapsin and CSP, z-stacks were obtained
using identical settings for all genotypes with same z-axis
spacing between them within the same experiment and
optimized for detection without saturation of the signal.36
Ten synaptic boutons were analysed per NMJ using the
free hand tool from ImageJ (http://imagej.nih.gov/ij/), with
each point in the graphs representing the average of 10
synaptic boutons/NMJ.
BRP puncta number were manually counted in z-stacks
using ImageJ and the Cell Counter plugin to record the
total number of puncta per NMJ. Synapse surface area
was calculated by creating a mask around the HRP chan-
nel, that labels the neuronal membrane, using ImageJ
thresholding and 3D object counter.36 DA neurons were
manually counted through z-stacks using Cell Counter
plugin using the anti-TH staining and each hemisphere
represents an n number.30
Western blotting
Drosophila heads. Quantitative western blotting from
adult fly heads were performed as previously published
protocol.28 The following primary antibodies were used:
anti-Synapsin (1:500—DSHB 3C11), anti-Syntaxin
(1:1000—DSHB 8C3), anti-GFP (1:1000—Thermo
Fischer A6455), anti-beta actin (1:1000—Abcam Ab8227)
and anti-beta tubulin (1:1000—DSHB E3). Secondary
antibodies were IRDye 800 conjugated goat anti-rabbit
(1:10 000, Rockland Immunochemicals) and Alexa Fluor
680 goat anti-mouse (1:10 000, Invitrogen). The n num-
ber correspond to independent biological replicate con-
taining 5–10 fly heads/genotype (for details see
Supplementary material).
Analysis of neuronal function
The Steady State Visual Evoked Potential (SSVEP) assay
measured the output of the photoreceptors and second-
order lamina neurons using protocol described previous-
ly37 (for details see Supplementary material).
Behavioural analyses
Drosophila ARousal Tracking system
Drosophila ARousal Tracking (DART) was used to per-
form single fly tracking of age-matched mated females
using protocol described previously38,39 (for details see
Supplementary material).
Startle-induced negative geotaxis
Startle-induced negative geotaxis (SING) was used to as-
sess the locomotor ability of flies following a startle
stimulus to which flies display a negative geotaxis re-
sponse (modified from Ruan et al.39). A group of 10
mated age-matched female flies, per genotype, were trans-
ferred into the experimental tubes. After the tubes of all
genotypes tested being placed in custom-made apparatus,
flies were allowed to acclimatise for 20min. Control and
experimental groups were always assayed together by
tapping all the flies to the bottom of the tubes and allow-
ing them to climb as a negative geotaxis response. After
10 s, the number of flies that successfully climbed above
the 7 cm line was recorded. This assay was repeated five
times allowing 1min rest during between trials (for
details see Supplementary material).
Proboscis extension response—Akinesia assay
The proboscis extension response (PER) assay was per-
formed as protocol described previously37 (for details see
Supplementary material).
Human post-mortem tissue analysis
Brain tissue samples
Detailed description of brain samples, diagnose criteria
and neuropathological assessments have been previously
published.40 Brain tissue samples were provided from
Brains for dementia research network. Consent for aut-
opsy, neuropathological assessment and research were
obtained and all studies were carried out under the ethic-
al approval of the regional Ethical Review Board of
Stockholm (2012/910–31/4). Thirty cases in total/brain
regions were used for the western blot experiments.
Controls were defined as subjects with no clinical history
and no neuropathological evidence of a neurodegenerative
condition.
Quantitative western blotting
For western blot analysis, 500mg of frozen tissue was
homogenized in ice-cold buffer containing 50mM
TrisHCL, 5mM EGTA, 10mM EDTA, protease inhibi-
tor cocktail tablets and 2mg/ml pepstatin A dissolved in
ethanol:dimethyl sulfoxide 2:1 (Sigma). To minimize in-
ter-blot variability, 20 lg total protein/samples were
loaded in each lane of each gel on 7.5–10% SDS-poly-
acrylamide gel and then transferred to nitrocellulose
membrane (Immobilon-P, Millipore). After blocking,
membranes were incubated with primary antibodies fol-
lowed by HRP conjugated secondary antibody. The fol-
lowing primary antibodies were used: rabbit polyclonal
anti-LIPRIN-a3 (1:1000, Synaptic Systems 169 102);
Rabbit anti-LIPRIN-a4 (1:1000, Abcam—ab136305);
Rabbit anti-GAPDH (1:5000, Abcam, ab22555).
Secondary antibodies used were donkey anti-rabbit
(1:10 000, Invitrogen NA9340V) or donkey anti-rabbit
(1:5000, LICOR, 926–32213) (for details see
Supplementary material).








































































GraphPad Prism 8 was used to perform the statistical
analyses. Comparison of means were performed using
either t-test; one-way ANOVA or KruskalWallis test
followed by Dunnett’s, Tukey’s or Dunn’s multiple com-
parison post hoc tests. The significance was defined as
P< 0.05, error bars are shown as SEM. For complete de-
scription, see Supplementary material.
Data availability
The data supporting the findings of this study are avail-
able within the article and in Supplementary material.
Results
a-Syn accumulates in presynaptic
terminals
To investigate the consequences of a-syn accumulation on
synapse structure and function, we used transgenic
Drosophila to express human wild-type a-syn fused to
EGFP (UAS-WT-a-syn-EGFP) alongside with control ani-
mals expressing EGFP only (UAS-EGFP).32 This genetic
model is an invaluable tool to investigate the toxic gain-
of-function of a-syn as the Drosophila genome lacks a
homologue of the SNCA gene.41 We first compared the
expression pattern of a-syn with the respective EGFP con-
trol by using the pan-neuronal driver nSyb-Gal4. Using
immunohistochemistry, the localization and the expres-
sion pattern of a-syn were determined at the Drosophila
L3 larval NMJ by colocalization with cysteine string pro-
tein (CSP) and horseradish peroxidase (HRP) (Fig. 1A
and B). CSP labels boutons containing synaptic vesicles at
the presynaptic terminal42,43 while HRP labels synaptic
membranes44 (Fig. 1A). The control expressing EGFP
only and the experimental group expressing a-syn-EGFP
displayed co-localization with CSP (Fig. 1B). In addition,
EGFP and a-syn were also detectable in axonal domains
labelled with anti-HRP and devoid of synaptic boutons,
however, the EGFP expression pattern in these areas was
very distinct between control and experimental group
(Fig. 1B and C, arrowheads and dashed boxes). a-syn
immunolabelling was enriched in regions with a high
density of synaptic boutons. In order to quantify this
phenotype, EGFP intensity was measured in regions of
CSP-positive synaptic boutons, and in CSP-negative axon-
al regions, in both control and experimental conditions.
A ratio of EGFP intensity was calculated by dividing the
values obtained from synaptic boutons by values obtained
from axonal regions. Values 1 indicated that EGFP in-
tensity is similar in the two regions while values higher
than 1 identified a higher EGFP intensity in synaptic bou-
tons compared with axonal regions. The analysis revealed









































































Figure 1 a-Syn accumulates in synaptic boutons at the
Drosophila NMJ. (A) Third instar larval stage (L3) Drosophila (left)
was used to investigate presynaptic terminals (boutons) terminating
at the NMJ (middle). Immunohistochemistry assay reveals the
muscle fibres (grey) stained with phalloidin that binds to actin; the
axons descending from the motor neuron and terminating onto the
muscles are labelled with anti-HRP (green); and the presynaptic
terminal of the motor neuron labelled with anti-BRP (red). (B)
Representative image of NMJ of nSyb>EGFP and nSyb>WT-a-syn-
EGFP larvae immunostained with anti-GFP (green), anti-CSP (cyan)
and anti-HRP (magenta). Arrowheads indicate accumulation of WT-
a-syn-EGFP in synaptic boutons, which are immunolabelled with
anti-CSP while control EGFP is homogeneously expressed in
synaptic boutons and axonal regions devoid of CSP
immunoreactivity; dashed boxes show a higher magnification of the
areas indicated by the arrowheads. (C) Quantitative analysis of the
ratio of GFP fluorescence intensity between boutons and axons;
****P¼ 0.0001; mean 6 SEM shown for each genotype (n¼ 5–6
flies/genotype). Statistical analyses were performed using unpaired
two-tailed t-test. Scale bars: 10 mm.







































































that a-syn immunofluorescence was significantly higher in
synaptic boutons than in axons compared with the con-
trol NMJ expressing EGFP only (Fig. 1B and C;
Supplementary Table 1, arrowheads and dashed boxes).
These data suggest that a-syn accumulates predominantly
in presynaptic terminals and to a lesser extent in axonal
areas devoid of synaptic boutons in the NMJ.
Accumulation of a-syn affects
presynaptic proteins
Previous studies demonstrated that the levels of synaptic
proteins are altered in patients with Parkinson’s disease
and related disorders,24,25 however, it is unclear whether
and how a-syn accumulation might be related to the
disease. We, therefore, investigated whether presynaptic
accumulation of a-syn leads to alterations in the expres-
sion and/or localization of presynaptic proteins that are
essential for neurotransmission. We first used the larval
L3 NMJ to evaluate the effect of a-syn accumulation on
synaptic vesicle proteins CSP and Synapsin, the
SNARE complex proteins, SNAP-25 and Synaptobrevin,
and the synaptic vesicle-specific Ca2þ-binding protein
Synaptotagmin.
CSP is a synaptic vesicle protein whose loss-of-function
in Drosophila causes synaptic degeneration and
lethality.45,46 CSP acts as a chaperone in the presynaptic
terminal47,48 and has been shown to be altered in
Parkinson’s disease patients as well as in cellular models
inoculated with pre-formed fibrils of a-syn.25,49 We meas-
ured the expression levels and localization of CSP at the
larval NMJ by immunofluorescence, which revealed that
CSP levels but not its localization were downregulated in
synaptic boutons co-labelled with a-syn when compared
with EGFP controls (Fig. 2A). Quantification of mean
fluorescence intensity was performed as a proxy for ex-
pression level in single synaptic boutons revealed signifi-
cantly reduced CSP levels in larvae expressing a-Syn
compared with controls expressing EGFP only (Fig. 2B;
Supplementary Table 1).
We next examined the presynaptic protein Synapsin
which is associated with the cytoplasmic surface of the
synaptic vesicle membrane and plays a fundamental role
in regulating vesicle trafficking.50–52 We measured
Synapsin fluorescence intensity and localization in single
synaptic boutons of larvae expressing either EGFP as
control or a-syn (Fig. 2C). Quantitative analysis of
Synapsin fluorescence intensity revealed that a-syn accu-
mulation caused a reduction in Synapsin expression levels
in synaptic boutons, compared with the control group
(Fig. 2D; Supplementary Table 1); however, alterations in




















































































































Figure 2 Accumulating a-syn downregulates presynaptic proteins. (A) Confocal images of NMJ immunolabelled with anti-CSP, anti-
GFP and anti-HRP. (C) Confocal images of NMJ staining with anti-Synapsin, anti-GFP and anti-HRP. (B) Quantitative analysis of the
fluorescence levels of CSP revealed downregulation in the NMJ of nSyb>WT-a-syn-EGFP larvae compared with control; *P¼ 0.0248; mean6
SEM shown for each genotype (n¼ 6 flies/genotype). (D) Quantitative analysis of the Synapsin fluorescence levels showed downregulation in
the NMJ of nSyb>WT-a-syn-EGFP larvae compared with control; ****P< 0.0001; mean with SEM shown for each genotype (n¼ 12–13 flies/
genotype). Statistical analyses were performed using unpaired two-tailed t-test. Scale bars: 10 mm.







































































CSP and Synapsin, we did not observe any changes in
fluorescence intensity levels and localization of SNAP-25,
Synaptobrevin or Synaptotagmin (Supplementary Fig. 1).
To examine the progression of a-syn-mediated pre-
synaptic deficits, we assessed a-syn accumulation in adult
flies at Day 3 and 20 and performed western blots of
heads of flies expressing a-syn or EGFP (Fig. 3AC).
While the levels of EGFP were unchanged (P¼ 0.5777;
Fig. 3B; Supplementary Table 1), levels of a-syn were
increased over time (*P¼ 0.0411; Fig. 3C; Supplementary
Table 1). We then assessed the levels of Synapsin and
Syntaxin in adult flies, which revealed downregulated
Synapsin levels at Day 3 and 20 (3-DO: **P¼ 0.0024;
20-DO: **P¼ 0.0056; Fig. 3D and E; Supplementary
Table 1), similar to the phenotype observed in synaptic
boutons of the NMJ. The expression levels of Syntaxin, a
component of the SNARE complex53, were reduced at
Day 3 but only significantly downregulated at Day 20
when compared with control (3-DO: P¼ 0.2079; 20-DO:
*P¼ 0.0151; Fig. 3F and G; Supplementary Table 1).
Together, these findings indicate that a-syn accumulates
in the Drosophila brain, which in turn causes specific
alterations of presynaptic proteins, with CSP, Syntaxin
and Synapsin being especially susceptible to the deleteri-
ous effects of accumulating a-syn.
Presynaptic accumulation of a-syn
reduces AZ density
Given the impact of a-syn on presynaptic proteins, we
investigated whether the accumulation of a-syn may alter
the AZ in Drosophila. The AZ is a specialized presynap-
tic site required for vesicle docking and neurotransmitter
exocytosis, conveying speed and accuracy to synaptic
transmission.54–56 We used confocal and instant struc-
tured iSIM to NMJs labelled with anti-Bruchpilot (BRP)
(Fig. 4A and B). BRP encodes a cytoskeletal protein
essential for the structural integrity and the function of
electron-dense projection (T-bar) at the AZ.57,58
Expression and accumulation of a-syn in nSyb>WT-a-
syn-EGFP L3 larvae caused a reduction in the total
number of BRP-labelled AZ puncta compared with
control groups nSyb/þ and nSyb>EGFP (versus nSyb/þ
*P¼ 0.0189; versus nSyb>EGFP *P¼ 0.0492; Fig. 4C;
Supplementary Table 1). A detailed analysis accounting
also for the surface area of the NMJ labelled by anti-
HRP,59 revealed also a significant reduction in the total
number of puncta in nSyb>WT-a-syn-EGFP larvae, when
compared with controls (versus nSyb/þ *P¼ 0.0289 and
nSyb>EGFP *P¼ 0.03; Fig. 4D; Supplementary Table 1).
In contrast, neither the total number of synaptic boutons
(versus nSyb>EGFP P¼ 0.2976; Fig. 4E; Supplementary
Table 1) nor the morphology and the localization of BRP
puncta (Fig. 4B, dashed lines) were affected. Together
these data demonstrate that accumulation of a-syn alters
the AZ of presynaptic terminals.
a-Syn accumulation impairs
neuronal function
The core function of BRP is the maintenance of the
presynaptic AZ and thus synaptic homeostasis and func-
tion.57 The observed reduction of BRP-positive puncta
suggested that physiological defects could occur as a























































































































































































Figure 3 Progressive accumulation of a-syn affects
presynaptic proteins in ageing animals. (A-C) Expression
levels of WT-a-syn-EGFP expressed under the control of pan-
neuronal driver nSyb-Gal4 increased at 20 days of age compared
with the levels observed in fly brains at 3 days of age; *P¼ 0.0411,
ns—not significant P> 0.05, n¼ 7–9. Such accumulation was
specific for WT-a-syn-EGFP since the control flies expressing EGFP
only (A, B) showed no alteration in the expression levels of EGFP.
(D, E) The expression levels of the synaptic vesicle protein Synapsin
were reduced in flies expressing WT-a-syn-EGFP at Day 3
(**P¼ 0.0024) and 20 (**P¼ 0.0056) compared with control flies;
n¼ 3–6. (F, G) The expression levels of Syntaxin, a protein of the
presynaptic SNARE complex, also had its levels reduced at Day 20
in fly brain expressing WT-a-syn-EGFP compared with control;
*P¼ 0.0151, ns—not significant P> 0.05, n¼ 3–6. Mean6 SEM are
shown, statistical analyses were performed using unpaired two-
tailed t-test. Full uncropped blots are available in Supplementary
material.







































































investigate whether synaptic efficacy and neurotransmis-
sion were affected, we determined the SSVEP in adult
flies (Fig. 5). The SSVEP quantifies the physiological re-
sponse to flickering stimuli which generate frequency-
and phase-locked response components with a very high
signal-to-noise ratio (Fig. 5AC).37,60 In Drosophila, the
net response of flickering stimuli is mediated by retinal
photoreceptor cells together with lamina and medulla
neurons that are electrically linked (Fig. 5C and D).62
The visual response negatively correlates with dopamine
levels in the brain,63 with dopamine required to inhibit































































Figure 4 Presynaptic active zones are reduced by accumulating a-syn. (A) Confocal images of NMJ, immunolabelled with anti-
nc82/BRP and anti-HRP. (B) Dashed box represents the section of the NMJ (A) imaged with instant super resolution structured iSIM. (C)
Quantitative analysis of total number of BRP puncta that represents the AZs labelled with anti-nc82/BRP per NMJ; *P¼ 0.0189 compared
with nSyb/þ and *P¼ 0.0492 compared with nSyb>EGFP. (D) Number of BRP puncta normalized by the synaptic surface micrometres square
immunolabelled with anti-HRP; *P¼ 0.0289 compared with nSyb/þ and *P¼ 0.03 compared with nSyb>EGFP. (E) The total number of synaptic
boutons/NMJ was unchanged. All graphs are represented as mean 6 SEM shown for each genotype (n¼ 8 flies for nSyb/þ and nSyb>EGFP;
and nine flies for nSyb>WT-a-syn-EGFP). Statistical analyses were performed using one-way ANOVA test followed by Tukey’s multiple
comparison post hoc test. Scale bars: (A) 10mm and (B) 5 mm.







































































Our analysis revealed that lamina neurons in 3-day-old
TH>WT-a-syn-EGFP flies showed an increased SSVEP
response upon stimulation when compared with control
groups (versus TH/þ *P¼ 0.0313; versus TH>EGFP
*P¼ 0.0325; Fig. 5E; Supplementary Table 1). This re-
sponse was specific to lamina neurons, as photoreceptor
cells showed no alteration in their SSVEP response (ver-
sus TH/þ P¼ 0.9998; versus TH>EGFP P¼ 0.8261;
Fig. 5F; Supplementary Table 1). The difference in stimuli
response between the lamina and photoreceptor neurons
correlated well with the far more extensive DA innerv-
ation in the lamina than the photoreceptor layer
(Fig. 5D).37,60 Because dopamine inhibits the SSVEP re-
sponse,60 these data suggest that TH-Gal4 driven accu-
mulation of a-syn in DA neurons impaired synaptic
output of DA-rich lamina neurons, thereby reducing their
visual response inhibition which in turn resulted in an
increased SSVEP response.
Accumulation of a-syn progressively
impairs motor behaviour
Parkinson’s disease patients suffer from a variety of
motor symptoms ranging from resting tremor to bradyki-
nesia and akinesia, related to the reduction of striatal
dopamine.64 However, these symptoms only become clin-
ically apparent when a large proportion of DA neurons
have already been lost.5 We, therefore, investigated
whether the accumulation of a-syn and in turn the altera-
tions in presynaptic proteins would cause any motor defi-
cits in adult flies. We employed three independent assays
to quantify voluntary and reflexive motor behaviour, the
DART system,38 startle-induced negative geotaxis
(SING)30,65 and the proboscis extension response
(PER).66
We specifically targeted a-syn to DA neurons and first
determined anti-a-syn immunoreactivity in the adult brain
of TH>WT-a-syn-EGFP flies compared with TH>EGFP
controls. Anti-a-syn antibody staining was detectable in
DA cell bodies, their neuronal projections and in synaptic
terminals (Supplementary Fig. 2AL). Next, we measured
their spontaneous motor activity with DART at 3 and
20 days of age (Fig. 6A). The activity and speed of
TH>WT-a-syn-EGFP flies was greatly impaired at Day 3
(Fig. 6B and C; Supplementary Table 1) compared with
control flies TH-Gal4/þ and WT-a-syn-EGFP/þ.
Notably, both activity and speed were further reduced in
flies accumulating a-syn compared with controls at Day
20 (Fig. 6B and C; Supplementary Table 1). To better
understand the detrimental impact of a-syn on movement
patterns, we decomposed and analysed movement as
units. The first unit comprised the initiation of a motor
action (Fig. 6D, red arrows), the action initiation; the se-
cond unit was the bout length, depicting for how long
the flies maintain a bout of activity (Fig. 6D, dark grey
boxes); and the third unit was the inter-bout interval that
quantifies the duration of the pause between the end of a
previous and the beginning of a new bout of activity
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Figure 5 a-Syn accumulation in dopaminergic neurons
impairs visual response. (A) Steady-state visual evoked potential
(SSVEP) was measured in flies raised in the dark and restrained in a
Gilson pipette tip. The recording electrode was placed on the
surface of the eye, with a reference electrode in the mouthparts. A
full field blue light stimulus is provided from an LED. A pattern of 45
stimuli is provided, with different amounts of the 1F1 (12Hz) and
2F1 (15Hz) stimuli. (B) An example stimulus made up of 70%
contrast at 1F1, and 30% contrast at 2F1 and its response. (C) The
response (in B) is analysed by the Fast-Fourier Transform, revealing
that the visual system responds to the supplied frequencies (1F1,
2F1) but also to their multiples (2F1, 2F2) and to the sums and
differences (1F1þ 1F2; 1F2 1F1). Higher frequency harmonics are
also seen, notably 2F1þ 2F2. (D) Genetic dissection60,61 shows
that the majority of the 1F1 and 1F2 components come from the
photoreceptors, the 2F1 and 2F2 come from the lamina neurons,
and the 1F1þ 1F2, 1F1þ 1F2 and 1F2 1F1 from the medulla.
(AD) Modified after Afsari et al.60 and Petridi et al.37 (E) Flies
expressing WT-a-Syn-EGFP under control of TH-Gal4 driver
demonstrated a higher lamina neuron activity in the SSVEP, which is
known to negatively correlate with levels of dopamine in the brain;
*P¼ 0.03. (F) Photoreceptors of TH>WT-a-Syn-EGFP displayed no
alteration in their response compared with control groups; ns—not
significant P> 0.05, n¼ 6–11 flies/genotype. Mean6 SEM are
shown, statistical analyses were performed using one-way ANOVA
with Tukey’s multiple comparison post hoc test.
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Figure 6 Synaptopathy induced by a-syn accumulation causes progressive motor impairment and akinetic behaviour prior
to age-related dopaminergic neurodegeneration. (A) The DART system was used to measure spontaneous activity of individual flies
that were continuously recorded at five frames per second for 2 h, as set by the DART software using a USB-webcam. (B) Top: spontaneous
activity is reduced in 3-day-old flies (3-DO) expressing WT-a-syn-EGFP compared with controls; ****P< 0.0001, **P¼ 0.0071 (n¼ 90–100
flies/genotype). Bottom: spontaneous activity is further reduced in 20-day-old (20-DO) TH>WT-a-syn-EGFP when compared with controls;
****P< 0.0001 and ***P¼ 0.0002 (n¼ 30 flies/genotype). (C) Active speed of 3-day-old flies (3-DO) (top) and 20-day-old flies (20-DO) (top)
is impaired by WT-a-syn-EGFP expression; ****P< 0.0001. (D) Schematic of the activity metrics units. The initiation of a locomotor action
(red arrows) is called action initiation. Bout length is the length of a motor action (dark grey boxes); and the pause between the end and
beginning of a new motor action is called inter-bout interval (white boxes). (E) Top: the number of locomotor actions initiated by 3-day-old
(3-DO) TH>WT-a-syn-EGFP flies was reduced compared with the control group TH/þ; ****P< 0.0001 and ns—not significant. Bottom: the
locomotor actions initiated by 20-day-old (20-DO) TH>WT-a-syn-EGFP flies was reduced when compared with both controls; **P< 0.0011
compared with TH/þ and **P¼ 0.0097 compared with WT-a-syn-EGFP/þ control. (F) The length of each bout of activity was shorter in
TH>WT-a-syn-EGFP flies at 3 (top) and 20 (bottom) days of age, depicting their impaired ability of sustaining a locomotor action; **P¼ 0.0053;
****P< 0.0001. (G) The length between each bout of activity was longer in flies expressing WT-a-syn-EGFP at 3 (top) and 20 (bottom) days;
*P¼ 0.0108, **P< 0.0014, ****P< 0.0001. Box-and-whisker plots represent the median (horizontal line), 25 and 75% quartiles (box), and 5 and
95% quartiles (whiskers); statistical analyses were performed using KruskalWallis test with Dunn’s multiple comparison post hoc test. (H)
Custom-made apparatus used to perform startle induced negative geotaxis (SING) assay which allows all fly genotypes to be probed under
equal conditions simultaneously. (I) A group of 10 flies were placed in an assay tube containing 1 cm of fresh media and then allocated back in
the fly holder. Next, the holder was gently tapped allowing all the flies to reach the bottom of the tubes (t¼ 0 s). (J) After 10 s, the number of
flies that successfully climbed above the 7 cm line is recorded. (K) Cohorts of flies were analysed at 3, 10, 20, 30 and 40 days of age. The
analysis showed an age-related deficiency in their climbing performance which was further enhanced by the overexpression of WT-a-syn-
EGFP; ****P< 0.0001; mean 6 SEM are shown, n¼ 9–13 groups of 10 flies. PER assay evaluated the ability of flies to respond to sucrose offer
after starvation. (L) Flies were fixed in a card (grey bar) with rubber cement and were left to recover for 3 h. (M) Starved flies were presented
with a droplet of 100mM of sucrose to the legs and then immediately scored; (N) flies that extended or not their proboscis in response to
sucrose were scored. (O) Young flies (5–8-day-old) expressing WT-a-syn-EGFP under control of TH-Gal4 driver showed a reduced response
to sucrose compared with controls flies, resembling an akinetic behaviour; *P¼ 0.03 and ****P< 0.0001; mean 6 SEM shown for each
genotype (n¼ 13–14 flies/genotype).







































































DA-specific expression of a-syn altered activity metric
parameters in 3-day-old flies (Fig. 6EG, top;
Supplementary Table 1). Three-day-old TH>WT-a-syn-
EGFP flies revealed a reduced ability to initiate loco-
motor movements compared with TH/þ controls
(Fig. 6E, top). In addition, TH>WT-a-syn-EGFP flies
showed a marked impairment in the capacity to maintain
a motor action, thus showing shorter bouts of activity
(Fig. 6F, top). Furthermore, these flies also displayed a
longer interval between each activity bout (Fig. 6G, top).
These alterations were also observed in 20-day-old
TH>WT-a-syn-EGFP flies when compared with controls
(Fig. 6EG). Together these data demonstrate that ex-
pression of a-syn in DA neurons caused an early onset of
abnormalities that affected spontaneous motor activity,
exemplified by shorter bouts of activity with reduced
speed and separated by longer pauses.
To investigate the impact of a-syn mediated motor im-
pairment over an extended period of time, we utilized the
SING assay which probes the ability of flies to climb to
the top of a tube after being gently tapped to the bot-
tom67,68 (Fig. 6HJ). Independent cohorts of flies either
expressing UAS-WT-a-syn-EGFP or UAS-EGFP were
aged and tested at 3, 10, 20, 30 and 40 days old for
their SING behaviour. nSyb>WT-a-syn-EGFP flies
showed a severe reduction in their climbing ability start-
ing at Day 20 compared with both control groups
(Fig. 6K; Supplementary Table 1). This phenotype wors-
ened as the flies reached 30 and 40 days of age, respect-
ively (Fig. 6K; Supplementary Table 1). These data
demonstrate that accumulation of a-syn and in turn alter-
ations in presynaptic proteins lead to progressive motor
deficits in ageing Drosophila.
To further investigate the impact of a-syn expression
on DA neuron function, we quantified the PER which is
modulated by a single DA neuron, the TH-VUM cell.69
PER behaviour measures the proboscis extension response
of flies to sugar stimuli after a short period of starvation
(Fig. 6LO).66 PER analysis showed the proportion of
TH>WT-a-syn-EGFP flies responding to sugar stimuli
was significantly lower compared with TH/þ and
TH>EGFP controls (Fig. 6O; Supplementary Table 1).
This data demonstrate that a-syn impairs the neural re-
sponse to sugar stimuli, most likely because the activity
of TH-VUM neuron is diminished. Thus, indicating that




The synaptopathy hypothesis suggests that synaptic dys-
function and the resulting behavioural deficits precede de-
generative cell loss. To test this hypothesis, we aged
TH>WT-a-syn-EGFP and control flies and quantified
DA neuron numbers in specific clusters of the ageing
Drosophila brain that were identified by
immunofluorescence with anti-tyrosine hydroxylase (TH)
antibody.30 We counted anti-TH-labelled DA neurons of
PPL1 and PPL2, PPM1/2 and PPM3 clusters in the adult
brain of 3, 20 and 40-day-old flies (Fig. 7A). At 3 days
of age, TH>WT-a-syn-EGFP flies showed no significant
loss of DA neurons in the PPL1 cluster compared with
the control groups (Fig. 7B and C; Supplementary Table
1). At 20-day-old, analysis of TH>WT-a-syn-EGFP flies
revealed a significant loss of DA neurons compared with
controls (Fig. 7B and C; Supplementary Table 1), which
was also observed in 40-day-old flies compared with age-
matched controls (Fig. 7B and C; Supplementary Table
1). Similar to PPL1, analysis of the PPM3 cluster revealed
a discrete loss of DA neurons at Day 20 when compared
with TH>EGFP control and TH/þ control at Day 40
(Fig. 7D; Supplementary Table 1). In contrast to PPL1
and PPM3, PPL2 and PPM1/2 clusters showed no signifi-
cant alteration in the number of DA neurons over time
due to WT-a-syn overexpression (Fig. 7E and F;
Supplementary Table 1). Together these data demonstrate
that a-syn accumulation causes region-specific and pro-
gressive degeneration of DA neurons in the ageing brain
of Drosophila.
AZ protein is downregulated in
human synucleinopathies
Our findings so far indicate that presynaptic a-syn accu-
mulation caused AZ deficits that resulted in decreased
neuronal function and behavioural deficits in ageing
Drosophila that occurred prior to progressive neurode-
generation. To evaluate the clinical significance of these
in vivo findings, we examined whether AZ proteins were
also altered in patient brain. For this, we re-analysed our
previously published proteomics data that compared 32
post-mortem human brains in the prefrontal cortex of
patients with PDD, DLB, Parkinson’s disease and older
adults without dementia.40 Our previous analysis identi-
fied alterations in synaptic proteins that correlated with
the rate of cognitive decline and reliably discriminated
PDD from Alzheimer’s disease patients.40 Here we
focussed on proteins enriched in the mammalian pre-
synaptic AZ, including homologs of the RIM, PICCOLO,
ELKS and LIPRIN-a protein families (Supplementary
Table 2). Our initial analysis indicated potential altera-
tions in AZ protein levels in patient brain, in particular
LIPRIN-a proteins (Supplementary Table 2).
Liprin-a3 and 4 proteins of the mammalian AZ play
crucial roles in synapse assembly and function.70 In mam-
mals, Liprin-a3 is highly expressed in the brain while
Liprin-a4 has a lower abundance in the central nervous
system.70 To corroborate our proteomics data, we carried
out quantitative western blotting analysis of LIPRIN-a3
and 4 in post-mortem tissue of prefrontal cortex (BA9),
anterior cingulate cortex (BA24) and parietal cortex
(BA40) in control, PDD and DLB patient brain samples.
The demographics and neuropathological characteristics







































































of the subjects included in our analysis are shown in
Supplementary Table 3. Levels of LIPRIN-a3 were
unaltered in all brain regions evaluated from PDD
and DLB when compared with controls (Fig. 8AC;
Supplementary Table 4). In contrast, expression levels of
LIPRIN-a4 were significantly downregulated in the pre-
frontal cortex of DLB patients compared with control
patients (*P¼ 0.0349; Fig. 8B and C; Supplementary Table
4). On the other hand, no significant alteration was
observed in cingulate cortex (P¼ 0.1192) or in parietal cor-
tex (P¼ 0.8737; Fig. 8B and C; Supplementary Table 4).
Discussion
a-syn accumulation and aggregation is the defining patho-
genic feature of Parkinson’s disease and other synucleino-
pathies.3,5 a-syn pathology correlates with synaptic
deficits and subsequent synaptopathy before neurons are
lost.26,27,71 However, the mechanisms and cascade of
events underlying the pathogenic progression from a-syn
accumulation to synaptopathy and subsequent neurode-
generation are not well understood. Here we tested the
hypothesis of a-syn-mediated synaptopathy by expressing
the human wildtype form of a-syn in Drosophila, a well-
established model to study Parkinson’s disease and synu-
cleinopathy,41,72 and monitored its effect over time in the
ageing animal. Our findings indicate that targeted expres-
sion of human a-syn leads to its accumulation in pre-
synaptic terminals that caused downregulation of
presynaptic proteins CSP, Synapsin and Syntaxin and a
reduction in the number of AZ required for synaptic
transmission. In addition to synaptic alterations, a-syn
accumulation caused impaired neuronal function and
behavioural deficits leading to the progressive loss of DA
neurons in ageing flies. While our approach of targeted
a-syn overexpression may relate more closely to familial
forms of synucleinopathies, such as duplications and trip-
lications of the encoding SNCA locus,73 the observed
data resemble key features of the onset and progression
of Parkinson’s disease, PDD and DLB, and demonstrate
that accumulating a-syn can cause synaptopathy and pro-
gressive neurodegeneration. Our findings imply that one,
if not the first cytotoxic insult of a-syn pathology, is its
accumulation in presynaptic terminals, which impairs
presynaptic AZs, a phenotype we also observed in post-
mortem tissue of DLB patients. The resulting impaired
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Figure 7 a-Syn-mediated synaptopathy causes progressive and age-related dopaminergic neurodegeneration. (A) Schematic
depiction of dopaminergic (DA) neuron clusters in the adult Drosophila brain; paired posterior lateral 1 and 2 (PPL1 and PPL2), the paired
posterior medial 1 and 2 (PPM1/2) and paired posterior medial 3 (PPM3). (B) Representative iSIM images from DA neurons from PPL1
clusters immunolabelled with anti-TH antibody. (C) Number of DA neurons per hemisphere from the PPL1 cluster is reduced at Day 20 and
40 compared with controls; **P¼ 0.0016, *P¼ 0.0146 for Day 20; *P¼ 0.0207 compared with TH/þ; *P¼ 0.0425 compared with WT-a-syn-
EGFP/þ for Day 40. (D) PPM3 clusters displayed a discrete loss of DA neurons in TH>WT-a-syn-EGFP flies only when compared with
TH>EGFP at Day 20 (*P¼ 0.0292) and to TH/þ at Day 40 (*P¼ 0.0333). (E, F) DA neurons from PPL2 and PPM1/2 clusters were not
affected by the expression of a-syn; n¼ 22–38 hemispheres/genotype; ns—not significant P> 0.05. Mean6 SEM shown, statistical analyses
were performed using one-way ANOVA with Tukey’s multiple comparison post hoc test. Scale bar ¼ 10 lm.







































































behavioural output, which over time leads to progressive
neurodegeneration.
Our findings are in line with post-mortem studies
where a-syn was found as small aggregates in the pre-
synaptic terminal.19,20 Dendrites and spines of DLB
patients with accumulation of aggregated a-syn were sig-
nificantly smaller than those without a-syn and correlated
with reduced expression levels of presynaptic proteins.19
These findings in human patient material resemble synap-
tic phenotypes we observed as a result of targeted a-syn
accumulation in Drosophila; they support recent experi-
mental findings, which indicate that aggregated a-syn can
directly bind and sequester presynaptic proteins.74
Together with our findings, these data identify presynap-
tic deficits and the resultant synaptopathy as a conserved
pathogenic pathway of accumulating a-syn.
In addition to alterations in presynaptic proteins, we
also detected a-syn-mediated loss of BRP puncta in
Drosophila. BRP is required for the structural integrity
and function of synaptic AZs,57 responsible for vesicle
docking and exocytosis of neurotransmitters.54,56
Downregulation or mutational inactivation of BRP has
been shown to impair T-bar formation and to reduce
evoked synaptic transmission and quantal content.57 As a
result, the neuronal function is affected, resulting in
impaired behaviour, which is illustrated by the name
Bruchpilot, meaning ‘crash pilot’ in German, referring to
the significantly impaired manoeuvring of BRP mutant
flies.57 Given BRPs core function, reduced numbers of
BRP-positive AZs would predict reduced synaptic efficacy
and impaired neural transmission in flies that accumulate
a-syn in presynaptic terminals. Indeed, quantification of
the SSVEP37,60 revealed altered synaptic efficacy caused
by a-syn accumulation in TH>WT-a-syn-EGFP flies.
These observations in Drosophila are in line with a re-
cent study in rodents which showed that overexpression
of a-syn caused impairment in the electroretinogram and
loss of TH positive amacrine cells in the retina.75
Consistent with impaired synaptic transmission, we
found that adult flies expressing a-syn in DA neurons dis-
played behavioural deficits in spontaneous locomotor ac-
tivity. Three-day-old TH>WT-a-syn-EGFP flies showed a
marked reduction in activity and speed, accompanied by
a significantly decreased ability to initiate and maintain
motor actions, together with longer pauses between each
bout of activity. These a-syn-mediated motor phenotypes
became more pronounced in older flies, revealing an age-
related progression of the disease that has also been
observed in other Drosophila models of Parkinson’s dis-
ease.32,41,76–79 In addition, flies accumulating a-syn also
displayed akinetic behaviour which was measured by the
proboscis extension response that evaluates the response
to sugar stimuli, a motor behaviour that is modulated by
a single DA cell, the TH-VUM neuron.69 Remarkably,
TH>WT-a-syn-EGFP flies showed a significant reduction
in their PER response, suggesting that a-syn accumulation
impairs neuronal function.
















































































































































































Figure 8 Active zone protein is affected in human synucleinopathy. (A, B) Quantitative western blots revealed no significant
alteration in the expression levels of LIPRIN-a3 in the prefrontal cortex (BA9), cingulate cortex (BA24) and parietal cortex (BA40), while
LIPRIN-a4 (B) was found to be downregulated in prefrontal cortex of DLB patients *P¼ 0.0389; (n¼ 8–10). (C) Representative images from
the western blotting membranes. All graphs are represented as mean6 SEM shown. Statistical analyses were performed using one-way
ANOVA test followed by post hoc Dunnett’s multiple comparison test. Full uncropped blots are available in Supplementary material.







































































This conclusion is further supported by the observed a-
syn-mediated alterations in the SSVEP that is regulated
by DA-rich lamina neurons in the adult brain of
Drosophila.37,60 a-syn accumulation also caused progres-
sive deficits in negative geotaxis, a startle induced loco-
motor behaviour that is controlled by dopamine in the fly
brain.32,41,68,79–81 These findings demonstrate that a-syn-
mediated synaptic alterations and impaired neurotransmis-
sion cause motor deficits in Drosophila affecting voluntary
behaviour including action initiation and maintenance, as
well as reflex activity. Comparable phenotypes have been
observed in rodent models of synucleinopathies and
patients with a-syn pathology (reviewed by Lashuel et al.92
and Bridi and Hirth5). Together these data strongly suggest
that presynaptic accumulation of a-syn causes synaptop-
athy and progressive behavioural deficits.
Accumulation and aggregation of a-syn are believed to
cause a vicious cycle in DA neurons, triggering further
accumulation of a-syn and neuronal cell death.5 Our
experiments in Drosophila demonstrate that accumulating
a-syn causes progressive degeneration of DA neurons in
an age-related manner. Interestingly, a-syn accumulation
preferentially affected both PPL1 and PPM3 cluster of
DA neurons that regulate motor behaviour and are
specifically affected in Drosophila models of Parkinson’s
disease.76,82–84 These findings resemble what is seen in
Parkinson’s disease patients where the reduction in
nigrostriatal pathway connectivity occurs prior to the de-
generative cell death of DA neurons in the substantia
nigra pars compacta.21,26 Of note, the progression of
degenerative cell loss in Drosophila correlated with the
progressive accumulation of a-syn levels in the ageing
animal, illustrating a key characteristic of synucleinopa-
thies, especially Parkinson’s disease, in that specific
populations of DA neurons are particularly vulnerable to
a-syn burden which directly correlates with disease sever-
ity and extent of neurodegeneration.85
Alterations in synaptic proteins have been reported in
clinical studies of Parkinson’s disease, PDD and DLB
patients with a-syn pathology. These studies suggest that
axonal and synaptic alterations correlate with cognitive
decline and the severity of the disease.24,25 In vivo studies
showed that reduced expression of a-syn was able to
ameliorate neurotoxicity and behavioural deficits in
conditional transgenic mice.86 Furthermore, in a transgen-
ic model of DLB/Parkinson’s disease, pharmacological tar-
geting of accumulating a-syn was sufficient to improve
behavioural alterations and to ameliorate neurodegenera-
tion.87 More recent findings indicate that the process
of Lewy Body formation, rather than fibril formation of
a-syn, is linked to synaptic dysfunctions that occur before
the early onset of neurodegeneration.88 These findings are
in line with our observations in Drosophila, which reveal
insights into early pathogenesis whereby the presynaptic
accumulation of a-syn affects synaptic proteins and
impairs AZ-mediated neuronal function. Consistent with
our findings in Drosophila, we found that the AZ matrix
protein Liprin-a4 is downregulated in the prefrontal
cortex of DLB patients which display Parkinsonian
phenotypes along with dementia.20,40 Despite a-syn
pathology being the defining feature of DLB, this disorder
is often accompanied by other age-related neurodegenera-
tive pathologies such as amyloid plaques and tau tan-
gles89 that may contribute to the observed phenotypes,
which remains to be determined. Nevertheless, our
findings are consistent with a pathogenic mechanism
where synaptic alterations directly correlate with
cognitive decline in Parkinson’s disease, DLB and PDD
patients.40
Taken together, our results presented here indicate a-
syn accumulation in presynaptic terminals affects synaptic
proteins and AZ integrity that impair neuronal function.
The resultant synaptopathy causes behavioural deficits
and progressive age-related neurodegeneration. This suc-
cession of phenotypes recapitulates key events of dying-
back like neurodegeneration5,27,90 and provide insights
into the pathogenic mechanisms underlying synaptopathy,
the likely initiating event in Parkinson’s disease and
related synucleinopathies.
Supplementary material
Supplementary material is available at Brain
Communications online.
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